Analysts are intrested in these 5 stocks: ( (TEVA) ), ( (ALAB) ), ( (COIN) ), ( (CROX) ) and ( (PDD) ). Here is a breakdown of their recent ratings and the rationale behind them.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Teva Pharmaceutical is catching the eyes of investors with a recent upgrade to ‘Buy’ by analyst Chris Schott. The company has announced a $700 million cost-cutting program, which is expected to drive significant margin expansion by 2027. This restructuring aims to reduce headcount and external spending, providing clarity on how Teva will achieve its 30% operating margin target. The company’s branded portfolio, including Austedo and the upcoming launches of Olanzapine LAI and Duvakitug, is well-positioned for growth, offsetting potential revenue headwinds from gRevlimid.
Astera Labs, Inc. is back in the spotlight with an upgrade to ‘Buy’ by analyst Joseph Moore. The semiconductor company is poised for growth, driven by the ongoing AI spending and new product launches. Despite a recent selloff, the current stock price presents an attractive entry point for investors. The company’s growth prospects remain strong, with expectations of significant revenue growth from new products and sustained retimer revenue.
Coinbase Global has seen mixed analyst opinions, with Ed Engel upgrading the stock to ‘Hold’ and Gautam Chhugani initiating coverage with a ‘Buy’ rating. The company is experiencing a potential mini ‘Alt Season,’ which could drive a resurgence in retail trading. Coinbase’s recent inclusion in the S&P 500 marks a significant milestone, symbolizing the crypto industry’s growing importance. Despite challenges, Coinbase remains a dominant player in the U.S. crypto market, with expectations of strong EPS growth.
Crocs is stepping up with an upgrade to ‘Buy’ by analyst Sam Poser, who has raised estimates and the price target significantly. The company has shown strong international revenue growth and better-than-expected HEYDUDE sales. Recent tariff reductions on Chinese goods present a positive outlook for Crocs, although the company faces challenges in managing tariff and demand uncertainties. The focus on brand equity and strategic execution could further enhance the company’s value.
PDD Holdings is gaining traction with an upgrade to ‘Buy’ by analyst Alicia Yap, following a positive tariff reduction outcome. The reduction in tariffs is expected to benefit Chinese cross-border sellers and boost Temu’s U.S. sales. Despite some risks, the company’s earnings outlook remains strong, with expectations of better-than-expected profits in the near term. The upgrade reflects a more favorable risk-reward profile for investors, with a significant expected share price return.